← All diseases
Liver, kidneys and digestion
Fatty liver disease (MASH/NASH), advanced
Do you want to receive a message when there is new research about Liver Fat (MASH/NASH), advanced? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, a single sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research on Liver Steatosis (MASH/NASH), Advanced is available. View what Premium costs.
Publications and studies (2550)
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Exercise Training Is Associated With Treatment Response in Liver Fat Content by Magnetic Resonance Imaging Independent of Clinically Significant Body Weight Loss in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. (2023/07/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis. (2023/07/01) ♡
- Diagnostic Performance of Noninvasive Tests for Advanced Hepatic Fibrosis in Young Age Population. (2023/07/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD - An Umbrella Overview of Systematic Review of Meta-Analysis. (2023/07/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Progress of research on the role of active ingredients of Citri Reticulatae Pericarpium in liver injury. (2023/07/01) ♡
- THE RELATIONSHIP BETWEEN TSH LEVELS, THYROID AUTOANTIBODIES AND ATHEROGENIC INDEX OF PLASMA, AST TO PLATELET RATIO INDEX SCORE, AND FIBROSIS 4 INDEX IN PATIENTS WITH HYPOTHYROIDISM. (2023/07/01) ♡
- Metabolic Muddle. MASLD and MASH on the Horizon. (2023/07/01) ♡
- Integrated serum pharmacochemistry, 16S rRNA sequencing and metabolomics to reveal the material basis and mechanism of Yinzhihuang granule against non-alcoholic fatty liver disease. (2023/06/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pharmacological properties and underlying mechanisms of aurantio-obtusin (Review). (2023/06/26) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report. (2023/06/13) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis. (2023/06/02) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. NAFLD and vitamin D: Evidence for intersection of microRNA-regulated pathways. (2023/06/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Non-alcoholic fatty liver disease in pregnancy. (2023/06/01) ♡
- Imaging Non-alcoholic Fatty Liver Disease Model Using H-1 and F-19 MRI. (2023/06/01) ♡
- Compatibility of Polygonati Rhizoma and Angelicae Sinensis Radix enhances the alleviation of metabolic dysfunction-associated fatty liver disease by promoting fatty acid β-oxidation. (2023/06/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Effect and mechanism of Dahuang Zhechong Pills in improving liver aging in rats by regulating ROS-mediated PI3K/Akt/FoxO4 signaling pathway]. (2023/06/01) ♡
- Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Garlic supplementation for the treatment of chronic liver disease: a meta-analysis of randomized controlled trials. (2023/06/01) ♡
- Loss of hepatic VMP1 trapped VLDL in the bilayer of endoplasmic reticulum membrane (☆). (2023/06/01) ♡
- [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease]. (2023/05/31) ♡
- Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. (2023/05/30) ♡
- Unraveling the Antioxidant Capacity of Spatholobi caulis in Nonalcoholic Fatty Liver Disease: A Multiscale Network Approach Integrated with Experimental Validation. (2023/05/13) ♡
- Sweeping 'Metabolic Dysfunction' off the Front Foot - Deceived by the “Wrong 'un”: Implications of Dysmetabolism Analysis in Healthy Subjects. (2023/05/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Fibroprogression and Cirrhosis Occurring in Living Liver Donor: First Case Report. (2023/05/01) ♡
- Ginsenoside RG3-enriched Korean Red Ginseng extract attenuates Non-Alcoholic Fatty Liver Disease by way of suppressed VCAM-1 expression in liver sinusoidal endothelium. (2023/05/01) ♡
- Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE (-/-) mice. (2023/04/30) ♡
- Lian-Qu formula treats metabolic syndrome via reducing fat synthesis, insulin resistance and inflammation. (2023/04/24) ♡
- A UPLC-Q-TOF/MS and network pharmacology method to explore the mechanism of Anhua fuzhuan tea intervention in nonalcoholic fatty liver disease. (2023/04/24) ♡
- A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease. (2023/04/20) ♡
- The convergent application of metabolites from Avena sativa and gut microbiota to ameliorate non-alcoholic fatty liver disease: a network pharmacology study. (2023/04/17) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Terminalia bellirica ethanol extract ameliorates nonalcoholic fatty liver disease in mice by amending the intestinal microbiota and faecal metabolites. (2023/04/06) ♡
- Si-Ni-San reduces lipid droplet deposition associated with decreased YAP1 in metabolic dysfunction-associated fatty liver disease. (2023/04/06) ♡
- Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD. (2023/04/01) ♡
- Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease. (2023/04/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection. (2023/04/01) ♡
- Non-alcoholic fatty liver disease (NAFLD) and COVID-19 outcomes: A systematic review, meta-analysis, and meta-regression. (2023/04/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The interplay between herbal medicines and gut microbiota in metabolic diseases. (2023/03/24) ♡
- Quantitative proteomics reveals Polygonum perfoliatum L. ameliorates hepatic steatosis by promoting PPARs/CPT1A/CPT2-mediated fatty acid β-oxidation. (2023/03/23) ♡
- Acupuncture improved hepatic steatosis in HFD-induced NAFLD rats by regulating intestinal microbiota. (2023/03/16) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial. (2023/03/10) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Characterizing the obesogenic and fatty liver-inducing effects of Acetyl tributyl citrate (ATBC) plasticizer using both in vivo and in vitro models. (2023/03/05) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Human milk-derived extracellular vesicles alleviate high fat diet-induced non-alcoholic fatty liver disease in mice. (2023/03/01) ♡
- Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. (2023/03/01) ♡
- Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease. (2023/03/01) ♡
- Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. (2023/03/01) ♡
- Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. (2023/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Nonalcoholic Fatty Liver Disease. (2023/03/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Index-based calculation or Transient Elastography to assess the degree of hepatic steatosis and fibrosis. (2023/03/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). (2023/03/01) ♡
- The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study. (2023/03/01) ♡
- Age-related liver endothelial zonation triggers steatohepatitis by inactivating pericentral endothelium-derived C-kit. (2023/03/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.